Literature DB >> 1729611

PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3' enhancer activity.

J M Pongubala1, S Nagulapalli, M J Klemsz, S R McKercher, R A Maki, M L Atchison.   

Abstract

PU.1 is a B-cell- and macrophage-specific transcription factor. By an electrophoretic mobility shift assay and dimethyl sulfate methylation interference assays, we show that PU.1 binds to DNA sequences within the immunoglobulin kappa 3' enhancer (kappa E3'). Binding of PU.1 to the kappa E3' enhancer assists the binding of a second tissue-restricted factor, NF-EM5, to an adjacent site. Binding of NF-EM5 to kappa E3' DNA sequences requires protein-protein interaction with PU.1 as well as specific protein-DNA interactions. This is the first known instance of PU.1 interacting with another cellular protein. NF-EM5 does not cofractionate with PU.1, suggesting that it is a distinct protein and is not a posttranslational modification of PU.1. UV-crosslinking studies and elution from sodium dodecyl sulfate-polyacrylamide gels indicate that NF-EM5 is a protein of approximately 46 kDa. Site-directed mutagenesis studies of the PU.1- and EM5-binding sites indicate that these sites play important roles in kappa E3' enhancer activity. By using a series of PU.1 deletion constructs, we have identified a region in PU.1 that is necessary for interaction with NF-EM5. This segment encompasses a 43-amino-acid region with PEST sequence homology, i.e., one that is rich in proline (P), glutamic acid (E), serine (S), and threonine (T).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1729611      PMCID: PMC364131          DOI: 10.1128/mcb.12.1.368-378.1992

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  42 in total

1.  Mechanism of action of an acidic transcriptional activator in vitro.

Authors:  Y S Lin; M R Green
Journal:  Cell       Date:  1991-03-08       Impact factor: 41.582

2.  I-POU: a POU-domain protein that inhibits neuron-specific gene activation.

Authors:  M N Treacy; X He; M G Rosenfeld
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

3.  Functional characterization of the developmentally controlled immunoglobulin kappa 3' enhancer: regulation by Id, a repressor of helix-loop-helix transcription factors.

Authors:  J M Pongubala; M L Atchison
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

4.  Interactions of the Oct-1 POU subdomains with specific DNA sequences and with the HSV alpha-trans-activator protein.

Authors:  T M Kristie; P A Sharp
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

5.  Transcriptional activation by the pseudorabies virus immediate early protein.

Authors:  K J Martin; J W Lillie; M R Green
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

6.  Characterization of a cellular factor which interacts functionally with Oct-1 in the assembly of a multicomponent transcription complex.

Authors:  M Katan; A Haigh; C P Verrijzer; P C van der Vliet; P O'Hare
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

7.  A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity.

Authors:  Y Nakabeppu; D Nathans
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

8.  The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1.

Authors:  R Paul; S Schuetze; S L Kozak; C A Kozak; D Kabat
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  IP-1: a dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylation.

Authors:  J Auwerx; P Sassone-Corsi
Journal:  Cell       Date:  1991-03-08       Impact factor: 41.582

10.  A novel upstream element compensates for an ineffectual octamer motif in an immunoglobulin V kappa promoter.

Authors:  M L Atchison; V Delmas; R P Perry
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

View more
  116 in total

1.  BSAP can repress enhancer activity by targeting PU.1 function.

Authors:  S Maitra; M Atchison
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  Mutants of ETS domain PU.1 and GGAA/T recognition: free energies and kinetics.

Authors:  F Pio; N Assa-Munt; J Yguerabide; R A Maki
Journal:  Protein Sci       Date:  1999-10       Impact factor: 6.725

3.  Mutation analysis of the Pip interaction domain reveals critical residues for protein-protein interactions.

Authors:  M A Ortiz; J Light; R A Maki; N Assa-Munt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.

Authors:  A L Brass; A Q Zhu; H Singh
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

5.  The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.

Authors:  E Torlakovic; A Tierens; H D Dang; J Delabie
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  Inhibition of CBP-mediated protein acetylation by the Ets family oncoprotein PU.1.

Authors:  Wei Hong; Alexander Y Kim; Sokun Ky; Carrie Rakowski; Sang-Beom Seo; Debabrata Chakravarti; Michael Atchison; Gerd A Blobel
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

7.  JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes.

Authors:  Leslie J Marshall; Lisa D Moore; Matthew M Mirsky; Eugene O Major
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

8.  Identification of a PU.1-IRF4 protein interaction surface predicted by chemical exchange line broadening.

Authors:  Scott R McKercher; Christian R Lombardo; Andrey Bobkov; Xin Jia; Nuria Assa-Munt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-07       Impact factor: 11.205

9.  Different binding site requirements for binding and activation for the bipartite enhancer factor EF-1A.

Authors:  G M Bolwig; J T Bruder; P Hearing
Journal:  Nucleic Acids Res       Date:  1992-12-25       Impact factor: 16.971

10.  Characterization of the human immunoglobulin kappa gene 3' enhancer: functional importance of three motifs that demonstrate B-cell-specific in vivo footprints.

Authors:  J G Judde; E E Max
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.